Related Experiment Videos
Avoiding untoward immune responses to novel gene products
1Immunology Dept, The University of Manitoba, Winnipeg, MB, Canada. sehona@ms.umanitoba.ca
Journal of Liposome Research
|February 27, 2003
Summary
Therapeutic gene transfection requires immunosuppression. A new method uses monomethoxypolyethylene glycol (mPEG) to create tolerogenic derivatives of antigens, enabling long-term, antigen-specific immune suppression for gene therapy.
Area of Science:
- Immunology
- Biotechnology
- Gene Therapy
Background:
- Successful gene therapy via transfection requires overcoming immune responses to the therapeutic gene product.
- Existing immunosuppression strategies may be non-specific or require repeated interventions.
Purpose of the Study:
- To develop a method for achieving antigen-specific, long-term immune suppression.
- To facilitate therapeutic gene transfection by mitigating immune rejection of the transgenic protein.
Main Methods:
- Coupling antigens to monomethoxypolyethylene glycol (mPEG) to create tolerogenic derivatives.
- Administering these mPEG-conjugated antigens to induce antigen-specific tolerance.
- Evaluating the suppression of antibody and cytotoxic T lymphocyte responses.
Main Results:
- Achieved long-term, antigen-specific suppression of both antibody and cytotoxic T lymphocyte induction.
- Demonstrated efficacy despite repeated administration of the antigen.
- mPEGylation of antigens effectively converted them into a tolerogenic form.
Conclusions:
- mPEGylation is a viable strategy for inducing antigen-specific tolerance.
- This method holds promise for improving the success of therapeutic gene transfection by preventing immune rejection.
- Enables repeated antigen administration without eliciting an immune response.